Format

Send to

Choose Destination
Bone Marrow Transplant. 2018 Mar;53(3):255-263. doi: 10.1038/s41409-017-0023-2. Epub 2017 Dec 18.

Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT.

Author information

1
University Medical Center Maastricht, Maastricht, Netherlands. gwendolyn.van.gorkom@mumc.nl.
2
University Medical Center Maastricht, Maastricht, Netherlands.
3
Dept. Medical Statistics & Bioinformatics, Leiden University Medical Center, Leiden, Netherlands.
4
Ospedale San Martino, Genova, Italy.
5
Medical Park Hospitals, Antalya, Turkey.
6
Ospedale San Raffaele s.r.l, Milano, Italy.
7
University Hospital, Essen, Germany.
8
Centre Hospitalier Universitaire Nantes, Nantes, France.
9
A.Z. Sint-Jan, Brugge, Belgium.
10
Institut Paoli Calmettes, Marseille, France.
11
'Sapienza' University, Rome, Italy.
12
University of Milano, Milano, Italy.
13
Istituto Clinico Humanitas, Rozzano, Italy.
14
Hospital Santa Creu i Sant Pau, Barcelona, Spain.
15
Hospital Clínico Universitario-INCLIVA, University of Valencia, Valencia, Spain.
16
Martin-Luther-Universität Halle-Wittenberg, Halle, Germany.
17
LMU-University Hospital of Munich-Campus Grosshadern, Munich, Germany.
18
Universitätsklinikum Jena, Klinik für Innere Medizin II, Abteilung für Hämatologie und Internistische Onkologie, Jena, Germany.
19
University of Cologne, Cologne, Germany.
20
University of Saarland, Homburg (Saar), Homburg, Germany.
21
University Medical Center Mainz, Mainz, Germany.
22
University Hospital of the Technical University Dresden & DKMS Clinical Trials Unit, Dresden, Germany.
23
University Hospital Eppendorf, Hamburg, Germany.

Abstract

Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation cyclophosphamide (PTCY). We analyzed patients with CLL who received an allogeneic HCT with a haploidentical donor and whose data were available in the EBMT registry. In total 117 patients (74% males) were included; 38% received PTCY as GVHD prophylaxis. For the whole study cohort OS at 2 and 5 yrs was 48 and 38%, respectively. PFS at 2 and 5 yrs was 38 and 31%, respectively. Cumulative incidence (CI) of NRM in the whole group at 2 and 5 years were 40 and 44%, respectively. CI of relapse at 2 and 5 yrs were 22 and 26%, respectively. All outcomes were not statistically different in patients who received PTCY compared to other types of GVHD prophylaxis. In conclusion, results of haploidentical HCT in CLL seem almost identical to those with HLA-matched donors. Thereby, haploidentical HCT is an appropriate alternative in high risk CLL patients with a transplant indication but no available HLA-matched donor. Despite the use of PTCY, the CI of relapse seems not higher than observed after HLA-matched HCT.

PMID:
29255169
DOI:
10.1038/s41409-017-0023-2

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center